Updated Jun 18, 8:01 PM · 60 sources analyzed
Key Takeaways
Regeneron's dupilumab Phase 2/3 bullous pemphigoid study completed; positive data could support another label expansion in rare dermatology.
Boehringer Ingelheim terminated its spesolimab long-term HS extension study, ceding ground to AbbVie and J&J in hidradenitis suppurativa.
Pfizer CFO Dave Denton departs for a role outside pharma, introducing uncertainty during a critical pipeline investment and restructuring period.
🏆 Winner
Regeneron Pharmaceuticals — dupilumab bullous pemphigoid study completion positions it for a potential new rare-skin-disease label with premium pricing upside.
📉 Loser
Boehringer Ingelheim — termination of the spesolimab HS long-term extension study effectively exits a high-value dermatology indication to better-positioned rivals.
🔭 Watch Next
Near-term data disclosures from completed trials — particularly Roche's adjuvant HCC Phase 3 and Regeneron's dupilumab bullous pemphigoid Phase 2/3 — will be the most consequential readouts visible in today's pipeline registry updates.
Regeneron dupilumab Phase 2/3 bullous pemphigoid study completed
Regeneron's dupilumab (an IL-4/IL-13 blocking antibody) completed a Phase 2/3 trial evaluating efficacy and safety in bullous pemphigoid, a rare autoimmune blistering skin disease with limited treatment options. The study status is now listed as completed on ClinicalTrials.gov, though specific endpoint figures have not been disclosed in today's sources. If results are positive, this could expand dupilumab's already broad label across inflammatory diseases and further entrench Regeneron's position in the dermatology market against emerging competitors.
ClinicalTrials.gov ↗Regeneron Pharmaceuticals
Dupilumab in Bullous Pemphigoid (rare autoimmune blistering skin disease)
Primary endpoint not disclosed in source. Study status listed as COMPLETED on ClinicalTrials.gov. Specific figures not disclosed.
Why it matters
Completion of this study sets up a near-term data readout that could support a supplemental BLA filing and widen dupilumab's multi-indication moat. Executives should monitor whether Regeneron files for label expansion ahead of IL-13 selective competitors entering this space.
Hoffmann-La Roche
Atezolizumab + Bevacizumab in Hepatocellular Carcinoma (liver cancer), adjuvant post-resection or ablation
Primary endpoint (recurrence-free survival or overall survival in adjuvant setting) not disclosed in source. Study status listed as COMPLETED on ClinicalTrials.gov. Specific figures not disclosed.
Why it matters
Completion signals a data readout is imminent; a positive result in high-risk resected HCC would open a new commercial front for atezolizumab/bevacizumab beyond first-line unresectable disease. Watch for presentation at ESMO or ASCO HCC-focused meetings.
Novo Nordisk
NDec (decitabine-tetrahydrouridine combination) in Sickle Cell Disease
Primary endpoints (efficacy and tolerability of NDec in sickle cell disease) not disclosed in source. Study status listed as COMPLETED on ClinicalTrials.gov. Specific figures not disclosed.
Why it matters
Completion of this Phase 2 study positions Novo Nordisk for a potential Phase 3 decision in sickle cell, a disease area where it currently has no marketed product and where emerging competition from gene therapies is intensifying pricing pressure on conventional agents. Data quality and fetal hemoglobin induction magnitude will be the key determinants of Phase 3 feasibility.
Boehringer Ingelheim
Spesolimab (anti-IL-36 receptor antibody) in Hidradenitis Suppurativa (HS, a chronic inflammatory skin disease causing painful nodules)
Long-term extension study terminated. Primary endpoint and specific figures not disclosed. Study terminated per ClinicalTrials.gov registry update.
Why it matters
This termination narrows spesolimab's commercial prospects to its approved generalized pustular psoriasis indication and suggests Boehringer Ingelheim may be reallocating resources away from HS, where the competitive bar has risen significantly. Rival HS programs should monitor whether this creates partnership or in-licensing opportunities for Boehringer.
Primary endpoint not disclosed in source. Study status listed as COMPLETED on ClinicalTrials.gov. Specific figures not disclosed.
Why it matters
Bullous pemphigoid is a high-unmet-need orphan-adjacent indication where approval would extend dupilumab's franchise into rare dermatology, a segment with premium pricing potential.
Analysis
Completion of this study sets up a near-term data readout that could support a supplemental BLA filing and widen dupilumab's multi-indication moat. Executives should monitor whether Regeneron files for label expansion ahead of IL-13 selective competitors entering this space.
Primary endpoint (recurrence-free survival or overall survival in adjuvant setting) not disclosed in source. Study status listed as COMPLETED on ClinicalTrials.gov. Specific figures not disclosed.
Why it matters
Adjuvant HCC is a highly competitive space where a positive result would be the first IO-based combination to demonstrate benefit after curative-intent surgery, competing directly with MSD's pembrolizumab adjuvant program.
Analysis
Completion signals a data readout is imminent; a positive result in high-risk resected HCC would open a new commercial front for atezolizumab/bevacizumab beyond first-line unresectable disease. Watch for presentation at ESMO or ASCO HCC-focused meetings.
Primary endpoints (efficacy and tolerability of NDec in sickle cell disease) not disclosed in source. Study status listed as COMPLETED on ClinicalTrials.gov. Specific figures not disclosed.
Why it matters
Sickle cell disease is a crowded but commercially important space following gene therapy approvals; an oral disease-modifying agent from Novo Nordisk would represent a lower-cost alternative with broader patient access potential.
Analysis
Completion of this Phase 2 study positions Novo Nordisk for a potential Phase 3 decision in sickle cell, a disease area where it currently has no marketed product and where emerging competition from gene therapies is intensifying pricing pressure on conventional agents. Data quality and fetal hemoglobin induction magnitude will be the key determinants of Phase 3 feasibility.
Long-term extension study terminated. Primary endpoint and specific figures not disclosed. Study terminated per ClinicalTrials.gov registry update.
Why it matters
Termination of the HS long-term extension study reduces the probability that spesolimab will gain an HS indication, leaving the field to AbbVie's bimekizumab and Johnson & Johnson's secukinumab.
Analysis
This termination narrows spesolimab's commercial prospects to its approved generalized pustular psoriasis indication and suggests Boehringer Ingelheim may be reallocating resources away from HS, where the competitive bar has risen significantly. Rival HS programs should monitor whether this creates partnership or in-licensing opportunities for Boehringer.
Primary endpoint (prevention of symptomatic laboratory-confirmed influenza vs. placebo; dose selection) not disclosed in source. Study status listed as COMPLETED on ClinicalTrials.gov. Specific figures not disclosed.
Why it matters
A successful dose-selection study for CD388 would enable Merck to advance a single-dose seasonal influenza prevention agent that could compete with or complement existing vaccines, addressing the significant unmet need in vaccine-hesitant or immunocompromised populations.
Analysis
Completion of this Phase 2 dose-finding study is a prerequisite for Phase 3 initiation; if a clean dose is identified, Merck could move toward a large prevention trial ahead of the next influenza season. Watch for conference presentation of dose-response data and any signal on durability of protection.
Denali Therapeutics
Denali Therapeutics sells a regulatory fast-pass (priority review voucher) for a Duchenne muscular dystrophy program, generating proceeds; a new Duchenne gene therapy received venture backing.
Why it matters
The PRV (priority review voucher — an FDA-issued certificate that can shorten review time by four months and be sold to any sponsor) sale generates immediate non-dilutive capital for Denali while signaling continued investor appetite for rare disease gene therapy platforms.
Analysis
PRV sales remain a viable near-term capital strategy for rare disease developers facing long commercialization timelines, and the venture backing for the new Duchenne gene therapy reflects sustained confidence in the gene therapy space despite recent setbacks elsewhere. Watch whether Denali deploys PRV proceeds toward its neurodegeneration pipeline or uses capital for business development.
GSK gonorrhea GMMA vaccine completes Phase 1/2 proof-of-concept study
GlaxoSmithKline completed a first-in-human proof-of-concept study of its Neisseria gonorrhoeae GMMA (generalized modules for membrane antigens — outer membrane vesicle-based) investigational vaccine in healthy adults aged 18–50, evaluating safety, reactogenicity, efficacy, and immunogenicity.
Why it matters
A demonstrated immunogenic and efficacious signal in this early study would validate the GMMA platform for sexually transmitted infection vaccines and could accelerate investment in a therapeutic area that has seen virtually no new approvals in decades.
Analysis
With gonorrhea rates at historic highs and antimicrobial resistance threatening last-line treatments, a viable vaccine platform would attract significant public health funding and partnership interest from governments and global health organizations. Executives in infectious disease and vaccine development should watch for immunogenicity data that correlates with protection endpoints.
AstraZeneca Phase 3 tezepelumab OCS-sparing trial terminated in corticosteroid-dependent asthma
AstraZeneca's Phase 3 randomized, double-blind, placebo-controlled study of tezepelumab for reducing oral corticosteroid (OCS) use in adults with OCS-dependent asthma was terminated before completion.
Why it matters
Termination of an OCS-sparing Phase 3 trial for a marketed biologic (tezepelumab is already approved for severe asthma) raises questions about whether the OCS-dependent subpopulation responds differently and may limit label expansion opportunities in this high-cost patient segment.
Analysis
Competitors with OCS-sparing data in severe asthma — including dupilumab and mepolizumab — maintain a differentiation advantage in this specific patient segment, and AstraZeneca will need to clarify termination rationale to reassure investors and prescribers about tezepelumab's broader positioning. Watch for any investor communication explaining whether termination was driven by futility, safety, or strategic reallocation.
Cardiol Therapeutics CardiolRx Phase 2 myocarditis recovery study completed
Cardiol Therapeutics completed a multi-center, double-blind, placebo-controlled Phase 2 study of CardiolRx (a pharmaceutical-grade oral cannabidiol formulation) in patients with acute myocarditis, evaluating myocardial recovery.
Why it matters
Acute myocarditis has no approved pharmacological therapy beyond supportive care; a signal of myocardial recovery benefit from an oral agent would open a new therapeutic category and could stimulate broader cannabidiol-based cardiology research.
Analysis
Study completion positions Cardiol Therapeutics for a Phase 2 data readout that, if positive, could significantly re-rate this small-cap company and attract partnership interest from larger cardiovascular-focused pharma. Investors should monitor for a forthcoming data presentation given the high unmet need and absence of approved alternatives.
Pfizer
Pfizer CFO Dave Denton steps down to take a role outside pharmaceuticals; company initiates search for successor.
Why it matters
Executive leadership turnover at the CFO level during a period of portfolio restructuring and patent cliff management introduces near-term uncertainty for Pfizer's capital allocation strategy and investor relations.
Analysis
A CFO departure during active pipeline investment and cost-reduction efforts may slow strategic decisions on business development and share buyback programs until a successor is confirmed. Investors should watch whether an internal or external candidate is selected, as an outsider hire could signal a shift in financial strategy.
Oral GLP-1 competing directly with Lilly and Novo. Best-in-class efficacy in Phase 2 at ~15% weight loss. Phase 3 success could make Viking an M&A target.
Regeneron's dupilumab completed a Phase 2/3 study in bullous pemphigoid per ClinicalTrials.gov; specific efficacy figures not yet disclosed but study completion sets up a near-term data release.
ClinicalTrials.gov ↗Pfizer CFO Dave Denton is stepping down to take a position outside the pharmaceutical industry; a search for a successor is underway. Pfizer also filed an 8-K Item 7.01 with the SEC on June 18, 2026.
BioPharma Dive ↗Novo Nordisk's Phase 2 study of NDec (decitabine-tetrahydrouridine) in sickle cell disease has been completed per ClinicalTrials.gov; efficacy and tolerability data are pending disclosure.
ClinicalTrials.gov ↗Cidara Therapeutics, now a Merck subsidiary, completed a Phase 2 dose-selection study of CD388 for influenza prevention in non-high-risk adults; results not yet disclosed.
ClinicalTrials.gov ↗AstraZeneca's Phase 3 tezepelumab oral corticosteroid-sparing study in OCS-dependent asthma was terminated before completion, per ClinicalTrials.gov. A separate AstraZeneca COVID-19 pre-exposure prophylaxis study (AZD3152, SUPERNOVA) also reached completed status.
ClinicalTrials.gov ↗Two Roche trials reached completed status on ClinicalTrials.gov: a Phase 3 adjuvant atezolizumab plus bevacizumab study in high-risk resected hepatocellular carcinoma, and a Phase 2 IV fixed-dose combination study of tiragolumab and atezolizumab in solid tumors.
ClinicalTrials.gov ↗Bristol Myers Squibb's Phase 2 study of BMS-986012 (anti-fucosyl-GM1 antibody) combined with carboplatin, etoposide, and nivolumab as first-line therapy in extensive-stage small cell lung cancer was completed per ClinicalTrials.gov; efficacy data not yet disclosed.
ClinicalTrials.gov ↗